Viewing nowMyeongmun Rosuvastatin Calcium Tablet 10 mg
Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication
Myeongmun Pharmaceutical Co., Ltd.

MFDS item code 201400005 · Approved 2014.01.02 · Insurance code 649806400
Improvement of dyslipidemia, reduction of cardiovascular disease risk, and inhibition of atherosclerosis progression
This medication is used as an adjunct in patients with primary hypercholesterolemia and mixed hyperlipidemia when dietary changes and exercise alone do not achieve control. It is also used as an adjunct to dietary changes or other lipid-lowering therapies in patients with homozygous familial hypercholesterolemia. It lowers total cholesterol and LDL cholesterol levels, delaying the progression of atherosclerosis and aiding the dietary management of patients with dysbetalipoproteinemia. It is effective in reducing the risk of cardiovascular disease, particularly in middle-aged patients with elevated high-sensitivity C-reactive protein levels and other cardiovascular risk factors, reducing the risk of stroke, myocardial infarction, and recurrence after arterial revascularization. Through these various effects, it plays an important role in improving cardiovascular health.
1. Primary hypercholesterolemia (type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Before and during treatment with this medicine, patients should follow a standard cholesterol-lowering diet and continue it throughout treatment. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 milligrams once daily, which is sufficient to control the condition in most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Assessment of renal function should be considered in these patients. There is no experience with use in patients with a Child-Pugh score above 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.
This medication should not be used in certain patients. For example, individuals who are allergic to this drug, those with severely impaired liver function, those with muscle disorders, those taking certain immunosuppressants, patients with severe renal impairment, women who are pregnant or breastfeeding, and women who are capable of becoming pregnant but do not use proper contraception should not take this medication. Additionally, liver function and muscle status should be regularly monitored before and during treatment with this medication, and those with a history of alcohol abuse or liver disease should exercise particular caution. If symptoms such as muscle pain or weakness occur, a doctor should be notified immediately, and if necessary, the medication can be discontinued. This medication contains lactose, so individuals with lactose intolerance or certain genetic metabolic disorders should not take it. This medication can interact with other drugs, so any other medications being taken should be disclosed to a physician or pharmacist. In particular, co-administration with certain antibiotics, antifungal agents, immunosuppressants, and fibrates may increase the risk of muscle-related side effects. Women who are pregnant or breastfeeding should not take this medication, and women who are capable of becoming pregnant should use appropriate contraception. If pregnancy is confirmed, the use of this medication should be immediately discontinued. In the case of overdose, since there is no specific antidote, immediate medical attention should be sought for appropriate treatment and evaluation. This medication may rarely cause side effects such as skin rash, headache, dizziness, gastrointestinal disturbance, muscle pain, and malaise; if serious skin reactions or liver dysfunction symptoms occur, immediate medical evaluation is required. Caution is needed as dizziness may occur while driving or operating machinery. When administering this medication to children and adolescents, assessment of growth and sexual development is necessary, and dose adjustment and caution are required.
Hypersensitivity reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, asthenia, polyneuropathy, amnesia, peripheral neuropathy, myasthenia gravis, cough, dyspnea, diarrhea, oculobulbar weakness, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lichenoid drug eruption, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, increased ALT, chest pain, muscle cramps, gout, erectile dysfunction, increased AST, numbness, dysesthesia, chest discomfort, anorexia, abdominal distension, syncope, myalgia, fatigue
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to protect it from air and moisture. The storage temperature should be kept at room temperature between 1°C and 30°C. This will help maintain the effectiveness and safety of the medication.
Pink round film-coated tablets
For domestic use - 30 tablets/bottle, for export - 30 tablets/box [(10 tablets/PTP*3)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowRosuvastatin Calcium 10.4mg
Tablet · Prescription medication
Myeongmun Pharmaceutical Co., Ltd.

Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication
AstraZeneca Korea Co., Ltd.

Rosuvastatin Calcium 20.8mg
Tablet · Prescription medication
AstraZeneca Korea Co., Ltd.

Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication
AstraZeneca Korea Co., Ltd.

Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication
Chong Kun Dang Pharmaceutical Corp.

Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication
Dong Gu Bio Pharmaceutical Co., Ltd.

Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication
Boryung Pharmaceutical Co., Ltd.

Rosuvastatin Calcium 20.8mg
Tablet · Prescription medication
Jongkundang Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.